Cargando…

Breast Cancer Heterogeneity

Breast tumor heterogeneity is a major challenge in the clinical management of breast cancer patients. Both inter-tumor and intra-tumor heterogeneity imply that each breast cancer (BC) could have different prognosis and would benefit from specific therapy. Breast cancer is a dynamic entity, changing...

Descripción completa

Detalles Bibliográficos
Autores principales: Fumagalli, Caterina, Barberis, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468623/
https://www.ncbi.nlm.nih.gov/pubmed/34573897
http://dx.doi.org/10.3390/diagnostics11091555
_version_ 1784573717971468288
author Fumagalli, Caterina
Barberis, Massimo
author_facet Fumagalli, Caterina
Barberis, Massimo
author_sort Fumagalli, Caterina
collection PubMed
description Breast tumor heterogeneity is a major challenge in the clinical management of breast cancer patients. Both inter-tumor and intra-tumor heterogeneity imply that each breast cancer (BC) could have different prognosis and would benefit from specific therapy. Breast cancer is a dynamic entity, changing during tumor progression and metastatization and this poses fundamental issues to the feasibility of a personalized medicine approach. The most effective therapeutic strategy for patients with recurrent disease should be assessed evaluating biopsies obtained from metastatic sites. Furthermore, the tumor progression and the treatment response should be strictly followed and radiogenomics and liquid biopsy might be valuable tools to assess BC heterogeneity in a non-invasive way.
format Online
Article
Text
id pubmed-8468623
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84686232021-09-27 Breast Cancer Heterogeneity Fumagalli, Caterina Barberis, Massimo Diagnostics (Basel) Review Breast tumor heterogeneity is a major challenge in the clinical management of breast cancer patients. Both inter-tumor and intra-tumor heterogeneity imply that each breast cancer (BC) could have different prognosis and would benefit from specific therapy. Breast cancer is a dynamic entity, changing during tumor progression and metastatization and this poses fundamental issues to the feasibility of a personalized medicine approach. The most effective therapeutic strategy for patients with recurrent disease should be assessed evaluating biopsies obtained from metastatic sites. Furthermore, the tumor progression and the treatment response should be strictly followed and radiogenomics and liquid biopsy might be valuable tools to assess BC heterogeneity in a non-invasive way. MDPI 2021-08-27 /pmc/articles/PMC8468623/ /pubmed/34573897 http://dx.doi.org/10.3390/diagnostics11091555 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Fumagalli, Caterina
Barberis, Massimo
Breast Cancer Heterogeneity
title Breast Cancer Heterogeneity
title_full Breast Cancer Heterogeneity
title_fullStr Breast Cancer Heterogeneity
title_full_unstemmed Breast Cancer Heterogeneity
title_short Breast Cancer Heterogeneity
title_sort breast cancer heterogeneity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468623/
https://www.ncbi.nlm.nih.gov/pubmed/34573897
http://dx.doi.org/10.3390/diagnostics11091555
work_keys_str_mv AT fumagallicaterina breastcancerheterogeneity
AT barberismassimo breastcancerheterogeneity